Comprehensive Safety Testing Shows Exenatide and Saxagliptin Cause No Pancreatic Damage in Animals | Research

The takeaway

Across more than 70 toxicology studies examining over 4,100 pancreata from mice, rats, dogs, and monkeys, neither exenatide nor saxagliptin caused any drug-related adverse effects on the pancreas — even at doses far exceeding human exposure.

4,100+ pancreata, zero harm
The most comprehensive preclinical pancreatic safety evaluation ever conducted for GLP-1-based drugs found no adverse effects across four animal species

What the researchers found

In the most comprehensive preclinical pancreatic safety assessment ever conducted for GLP-1-based drugs:

- More than 70 GLP-regulated toxicology studies were conducted across mice, rats, dogs, and monkeys

- Over 2,400 pancreata examined from exenatide-treated animals

- Over 1,700 pancreata examined from saxagliptin-treated animals

- Treatment lasted up to 2 years in rodents and 12 months in non-rodents

- Doses reached 130× human exposure for exenatide and 2,200× for saxagliptin

- Neither drug caused microscopic changes indicating acute or chronic pancreatic injury

- No evidence of pancreatitis, pre-neoplastic changes, or pancreatic cancer in any species

These data substantially support the pancreatic safety of GLP-1-based therapies.

Why it matters

This study provides the most definitive preclinical evidence addressing one of the biggest safety concerns ever raised about GLP-1 drugs — the fear that they cause pancreatitis or pancreatic cancer. With over 4,100 pancreata examined at extreme drug exposures, the complete absence of adverse findings provides powerful reassurance. This data was instrumental in regulatory agencies concluding that GLP-1 drugs do not pose a significant pancreatic risk.

How the study worked

This was a comprehensive integration of regulatory toxicology data from more than 70 non-clinical studies conducted under Good Laboratory Practice (GLP) regulations in accordance with ICH and FDA guidelines. Studies included mice, rats, dogs, and non-human primates. Comprehensive pancreas assessments evaluated endocrine and exocrine tissue for any drug-related microscopic changes at multiple time points and dose levels.

What this study cannot tell us

This is an industry-sponsored study from the manufacturer of exenatide and saxagliptin, which could introduce bias. Animal toxicology, even across multiple species, cannot perfectly predict human responses. The studies assessed histological endpoints — subclinical functional changes may not have been captured. Chronic low-grade inflammation without visible microscopic changes is theoretically possible. The 2-year maximum duration in rodents may not capture very long-term effects relevant to lifelong human use.

How to read the evidence

This represents the highest standard of preclinical safety evidence — GLP-compliant regulatory toxicology studies across multiple species, conducted under ICH/FDA guidelines. The scale (70+ studies, 4,100+ pancreata, up to 2,200× human doses) is unprecedented. However, it remains preclinical evidence and was industry-sponsored.

When this study was published

Published in 2014, this study addressed safety concerns that were urgent at that time. Since then, large-scale human safety data (including cardiovascular outcome trials with tens of thousands of patients) has corroborated these preclinical findings, further supporting the pancreatic safety of GLP-1 drugs.

The bigger picture

The pancreatitis and pancreatic cancer scare nearly derailed the GLP-1 drug class in its early years. This comprehensive safety evaluation, combined with subsequent large-scale human clinical data, has essentially settled the debate. The result has been continued expansion of GLP-1 drug approvals and prescribing, now extending well beyond diabetes to obesity, cardiovascular disease, and emerging neurological indications. This study played a key role in building the safety confidence that enabled that expansion.

Questions still open

Does the complete absence of pancreatic findings at extreme doses definitively close the safety question, or should ongoing pharmacovigilance continue?
Could the newer, more potent GLP-1 drugs (like high-dose semaglutide) have different pancreatic safety profiles than the drugs tested here?
Are there genetic or metabolic susceptibilities in certain human populations that animal testing cannot capture?

Common questions

Has the pancreatic cancer concern about GLP-1 drugs been resolved?

Largely yes. This study examined over 4,100 animal pancreata at extreme drug doses and found no evidence of cancer or pre-cancerous changes. Since then, large human studies with tens of thousands of patients have found no increased pancreatic cancer risk with GLP-1 drugs. Regulatory agencies (FDA, EMA) have reviewed all available evidence and concluded there is no confirmed causal link between GLP-1 drugs and pancreatic cancer.

Why were such extreme doses used in these studies?

Regulatory toxicology studies deliberately use doses much higher than what humans take — in this case up to 2,200 times human exposure — to maximize the chance of detecting any safety signal. The logic is: if a drug causes no harm at 2,200× the human dose, it is very unlikely to cause that type of harm at therapeutic doses. This is standard practice for evaluating drug safety before and during regulatory approval.

Read the original research

The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.

Diabetes, obesity & metabolism, 16(10), 910-21

View on PubMed ↗Publisher’s paper ↗

Citation

Roy, D; Chadwick, K D; Tatarkiewicz, K; LaCerte, C; Bergholm, A-M; Brodie, T; Mangipudy, R S; Parkes, D; Graziano, M J; Reilly, T P. (2014). The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.. Diabetes, obesity & metabolism, 16(10), 910-21. https://doi.org/10.1111/dom.12294